Can You Take Meloxicam with CYCLOBENZAPRINE HYDROCHLORIDE?
A plain-English look at the major interaction between Meloxicam (CIPLA MELOXICAM 7.5) and CYCLOBENZAPRINE HYDROCHLORIDE (CYCLOBENZAPRINE HYDROCHLORIDE) — what it means, why it happens, and what to talk to your doctor or pharmacist about.
Taking Meloxicam (CIPLA MELOXICAM 7.5) with CYCLOBENZAPRINE HYDROCHLORIDE (CYCLOBENZAPRINE HYDROCHLORIDE) is a major drug interaction that should be avoided. Excessive sedation, respiratory depression, falls. Additive CNS depression. Both classes cause sedation and respiratory depression through complementary pathways.
Not sure about your specific combination? Check it in the Drug Interaction Checker →
Key Takeaways
- Interaction severity: Major
- Risk: Excessive sedation, respiratory depression, falls.
- Mechanism: Additive CNS depression. Both classes cause sedation and respiratory depression through complementary pathways.
- Meloxicam: S4 in Australia, low risk
- CYCLOBENZAPRINE HYDROCHLORIDE: S4 in Australia, low risk
- Claims action: Flag for immediate prescriber review. Document intervention in claim file.
Meloxicam vs CYCLOBENZAPRINE HYDROCHLORIDE at a Glance
| Property | Meloxicam | CYCLOBENZAPRINE HYDROCHLORIDE |
|---|---|---|
| Brand names | CIPLA MELOXICAM 7.5, MELOBIC, APX-Meloxicam | CYCLOBENZAPRINE HYDROCHLORIDE |
| Drug class | opioid | muscle relaxant |
| Risk level | low | low |
| TGA Schedule (AU) | S4 | S4 |
Why Is This Combination Dangerous?
Additive CNS depression. Both classes cause sedation and respiratory depression through complementary pathways.
Regulatory Guidance by Jurisdiction
Australia TGA / SIRA / WorkSafe
The TGA and Australian Medicines Handbook classify this as a major drug interaction requiring immediate intervention.
United Kingdom NICE / MHRA / FPM
UK clinical guidelines recommend caution with this combination. For personal injury claims, the prescribing rationale should be documented and reviewed against NICE and FPM guidance.
United States FDA / CDC / State WC
The CDC and FDA recommend monitoring concurrent CNS depressant use. State workers compensation formularies may restrict or require prior authorization for this combination.
What Claims Professionals Should Do
- Flag immediately as a high-risk prescribing pattern in the claim file
- Request urgent prescriber review with documented clinical justification for the combination
- Consider an independent medical examination if the prescriber cannot provide adequate justification
- Assess work capacity impact as the combination significantly increases sedation and impairment risk
- Document all interventions for audit trail and compliance purposes
- Check Reasonable and Necessary status for both medications against the compensable injury
Clinical reference
A clinical summary of Meloxicam and CYCLOBENZAPRINE HYDROCHLORIDE drawn from regulator advisories, national guidelines, and authoritative drug references. Read this if you want the deeper clinical picture before talking to your prescriber or pharmacist.
Severity assessment
Informational. While there is no direct drug-drug interaction, both medications can cause additive side effects such as drowsiness and gastrointestinal upset.
Mechanism (plain English)
Cyclobenzaprine is a muscle relaxant that works on the central nervous system to reduce muscle spasms. It can cause drowsiness and has anticholinergic effects. Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that reduces pain and inflammation by inhibiting enzymes involved in prostaglandin synthesis. While their primary mechanisms of action are different and do not directly interfere with each other, both drugs can independently cause side effects that might be additive when taken together. For instance, cyclobenzaprine can cause central nervous system depression (like drowsiness), and meloxicam can cause gastrointestinal irritation. Combining them might increase the likelihood or severity of these individual side effects.
Evidence level
Theoretical. There are no documented direct drug-drug interactions between cyclobenzaprine and meloxicam in major drug interaction databases or regulatory advisories. The potential for additive side effects is based on the known pharmacological profiles of each drug.
Top regulator advisories (cite verbatim or close paraphrase)
- TGA (Australia): No pair-specific public advisory found. Applicable product information for Meloxicam (e.g., MOBIC meloxicam 15mg tablet blister pack, ARTG 77695) warns of cardiovascular and gastrointestinal risks associated with NSAIDs. Product information for cyclobenzaprine (not widely available in Australia) would typically advise on CNS depressant effects.
- MHRA / NICE (UK): No pair-specific guidance found. The British National Formulary (BNF) provides general guidance on NSAIDs and muscle relaxants, highlighting individual side effects. For example, NSAIDs carry warnings regarding gastrointestinal and cardiovascular risks, and muscle relaxants like cyclobenzaprine are known for sedative effects.
- FDA / CDC (US): No pair-specific safety communication found. The FDA label for cyclobenzaprine (e.g., FLEXERIL) warns of serotonin syndrome when used with other serotonergic drugs and interactions with MAO inhibitors, neither of which applies to meloxicam. The FDA label for meloxicam (e.g., DailyMed - MELOXICAM tablet) includes a Boxed Warning for serious cardiovascular thrombotic events and serious gastrointestinal adverse reactions, common to all NSAIDs.
- EMA (Europe): No pair-specific advisory found. EMA guidance for meloxicam (e.g., Mobic) would include warnings typical for NSAIDs regarding gastrointestinal, cardiovascular, and renal risks. Cyclobenzaprine is not widely marketed in Europe.
Clinical risk factors that elevate the danger
- Elderly patients: Increased risk of central nervous system (CNS) side effects (drowsiness, dizziness) from cyclobenzaprine and higher risk of gastrointestinal and cardiovascular adverse events from meloxicam.
- Patients with pre-existing gastrointestinal conditions: History of ulcers, bleeding, or inflammatory bowel disease increases the risk of meloxicam-induced GI complications.
- Patients with cardiovascular disease or risk factors: Increased risk of cardiovascular thrombotic events with meloxicam.
- Patients with renal impairment: Meloxicam can worsen kidney function.
- Concomitant use of other CNS depressants: Alcohol, opioids, benzodiazepines, or other sedatives can exacerbate cyclobenzaprine's sedative effects.
- Concomitant use of other NSAIDs or anticoagulants: Increases the risk of gastrointestinal bleeding with meloxicam.
What a patient should be told
- It is generally safe to take cyclobenzaprine and meloxicam together as prescribed by your doctor, but be aware of potential side effects.
- Both medications can cause drowsiness or dizziness. Avoid driving or operating heavy machinery until you know how they affect you. Be cautious when standing up to prevent falls.
- Meloxicam can irritate your stomach and, in rare cases, cause serious bleeding or ulcers. If you experience severe stomach pain, black or tarry stools, or vomit that looks like coffee grounds, seek urgent medical attention.
- Do not stop taking either medication suddenly without consulting your doctor or pharmacist. They can help you find safer alternatives if needed.
- Discuss all other medications, supplements, and herbal remedies you are taking with your healthcare provider to ensure there are no other potential interactions.
Top 3 sources (with full citation)
- Drugs.com. Cyclobenzaprine and Meloxicam Drug Interactions. Available at: https://www.drugs.com/drug-interactions/cyclobenzaprine-with-meloxicam-758-0-1549-0.html
- DailyMed. MELOXICAM tablet. U.S. National Library of Medicine. Updated September 16, 2025. Available at: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee8df8fa-d08a-8c8b-f048-813e5022a101
- FDA. FLEXERIL (CYCLOBENZAPRINE HCL) TABLETS. Label. Revised 2013. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017821s051lbl.pdf
Notes for the reviewing pharmacist
While direct interactions between cyclobenzaprine and meloxicam are not typically cited, the primary concern lies in the additive nature of their individual side effect profiles. Cyclobenzaprine, a centrally acting muscle relaxant, contributes to CNS depression, which can be particularly problematic in older adults or those concurrently using other sedating agents. Meloxicam, an NSAID, carries inherent risks of gastrointestinal toxicity (bleeding, ulceration) and cardiovascular events, which are class effects. Pharmacists should counsel patients on recognizing and reporting symptoms of excessive sedation or GI distress. It is crucial to assess the patient's overall medication regimen for other CNS depressants or agents that increase GI/CV risk. The absence of a specific interaction warning does not equate to an absence of risk, especially in vulnerable populations. The recall of cyclobenzaprine tablets due to mislabeling with meloxicam, while not a drug interaction, highlights the potential for serious adverse events if meloxicam is inadvertently taken by patients for whom it is contraindicated or at higher risk. This underscores the importance of patient education on medication identification.
Source metadata JSON
Check this medication against your full medication list
Check all interactions for Meloxicam and CYCLOBENZAPRINE HYDROCHLORIDE across your claimant's full medication list.
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.
Related Resources
Important: This page is general health information, not personal medical advice. If you have questions about your medication — including starting it, stopping it, changing the dose, or combining it with something else — speak with your doctor or pharmacist. For an emergency or suspected overdose, call your local emergency number or poison information service immediately. Information is drawn from regulator and clinical guideline sources (TGA, FDA, MHRA, NICE, PBS, CDC); see our methodology for details.